Combined Dyslipidemia: Should the Focus be LDL Cholesterol or Atherogenic Dyslipidemia?

E-ISSN： 1873-4286|19|21|3858-3868

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.19, Iss.21, 2013-06, pp. : 3858-3868

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Effect of Fenofibrate on the Concentration and Relative Distribution of LDL Subfractions in Patients with Combined Dyslipidemia

Letters in Drug Design & Discovery, Vol. 1, Iss. 4, 2004-10 ,pp. : 380-383

Bentham Science Publishers

Access to resources Recommend Favorite

Cardiovascular Disease and Dyslipidemia: Beyond LDL

Current Pharmaceutical Design, Vol. 17, Iss. 9, 2011-03 ,pp. : 861-870

Bentham Science Publishers

Access to resources Recommend Favorite

Cilostazol and atherogenic dyslipidemia: a clinically relevant effect?

By Rizzo Manfredi Corrado Egle Patti Angelo Maria Rini Giovam Battista Mikhailidis Dimitri P

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 4, 2011-03 ,pp. : 647-655

Informa Healthcare

Access to resources Recommend Favorite

PPAR Agonists, Atherogenic Dyslipidemia and Cardiovascular Risk

Current Pharmaceutical Design, Vol. 23, Iss. 6, 2017-03 ,pp. : 894-902

Bentham Science Publishers

Access to resources Recommend Favorite

Micronized Fenofibrate in Dyslipidemia: A Focus on Plasma High-Density Lipoprotein Cholesterol (HDL-C) Levels

By Sharpe M. Ormrod D. Jarvis B.

American Journal of Cardiovascular Drugs, Vol. 2, Iss. 2, 2002-02 ,pp. : 125-132

Adis International

Access to resources Recommend Favorite